Skip to main content
Equibles
DRMA logo

DRMA · Dermata Therapeutics, Inc.

Track DRMA — free

Use DRMA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about DRMA

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.42 +0.04 (+2.90%) At close · Aug 21
Going-concern doubt — flagged Aug 11, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Because of historical and expected operating losses and net operating cash flow deficits, there is substantial doubt about the Company's ability to continue as a going concern for one year from the issuance of the financial statements, which is not alleviated by management's plans.”
View the 10-Q filed Aug 11, 2026
Market Cap
$5.71M
Shares
4.02M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.42 Open$1.38 Day$1.36–1.47 52W close$1.08–5.91 Avg vol 30d1.5M Short int51K · 1.3% float · 1.0d Short vol43% Last earningsNov 15, 2021 DataAug 2025–Aug 2026 Filing10-Q · Aug 11

Raw chart and full-history price indicators begin at the captured split on Aug 1, 2025; bars on opposite sides are not compared.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 11, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 15.1 · calm Equity put/call 0.51
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −16%
below
Price vs 50-day avg +11%
above
RSI (14) 57
neutral
MACD trend Positive
52-week position 7%
near low
Volume (OBV) Bearish div.
distributing
Momentum
relative strength
Strong
1-month return +8%
trailing
6-month return +23%
trailing
YTD return −39%
this year
Relative strength +12%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+88% holders QoQ · +8 funds added
Insider flow Distributing
Net -$13 over 90 days · 100% sells
Short interest Falling
1.26% of float · ▼ -21.7% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
15 holders — near 3-yr high, broad support
Squeeze score 54
elevated · 0–100
Fundamentals
Excellent
EPS growth +90%
Y/Y
Balance sheet $6.4M
net cash
Quant / Vol
risk profile
Very High
Volatility 124%
annualized · 1-yr
Max drawdown −82%
past year
ATR 9.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
3 · 2 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−16% Bearish
Price vs 50-day avg
+11% Bullish
RSI (14)
57 Neutral
MACD trend
Positive Bullish
52-week position
7% Bearish
Volume (OBV)
Bearish div. Bearish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+88% holders QoQ · +8 funds added
Insider flow Distributing
Net -$13 over 90 days · 100% sells
Short interest Falling
1.26% of float · ▼ -21.7% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
15 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $1 · 7% Range high $6
vs 200-day avg -16% vs 50-day avg +11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
DRMA
Dermata Therapeutics, Inc.
this stock
$5.71M -38.8% — — 1.3%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $138.91B +20.9% +46.2% 31.9 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $85.87B +8.1% +20.8% 20.7 3.3%
ARGX
Argenx SE
 $64.66B +23.6% — — 2.1%
CSLLY
Csl Ltd
 $57.97B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
15
% held
3.7%
Net QoQ
+27.6K sh
Top holder
GEODE CAPITAL MANAGEMENT,…
Held Float
View
Held by Funds
Fund positions
2
View
Short & Settlement
Short Interest Falling
Shares short
50.8K
Days to cover
1.0d
Change
-14.1K sh
View
Short Volume
Short vol %
43%
As of
Aug 21, 2026
Short Total
View
Fails to Deliver
FTD shares
756
Value
$937
As of
Jul 29, 2026
View
Off-Exchange
Off-exchange %
70.2%
Week of
Jul 13, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$13
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-7.6M
EPS diluted
$-8.16
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 17, 2026
This year
13
View
Exempt Offerings
Offering
$4.1M
Filed
Jan 7, 2026
View
Earnings & Events
Earnings Calls
Last call
Nov 15, 2021
View

Performance

Raw-price comparisons begin at the captured split on Aug 1, 2025; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
DRMA -2.7% +7.6% +23.5% +21.4% -38.8%
SPY -1.4% +3.6% +11.6% +2.5% +12.3%
vs SPY -1.4% +4.0% +11.9% +18.9% -51.1%
Key facts CIK 1853816 CUSIP 249845504 13F (30d) 13 filings 13 filers Visit website

Report a Problem

Category
Description
Email (optional, for follow-up)